Skip to content

Axsome Therapeutics AXSM Operating Lease ROU Assets

Operating Lease ROU Assets at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
Arrowhead Research logo
Arrowhead ResearchARWR
Biogen logo
BiogenBIIB
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Revenue$191.2M+57.4%
Gross profit$176.5M+58.0%
Operating income-$63.4M-11.2%
Net income-$64.5M-8.6%
EPS (diluted)-$1.26-3.3%

Balance sheet

See full
Cash & equivalents$305.1M+1.4%
Total debt$219.9M+4.1%
Total equity$54.6M+2.6%
Total assets$713.6M+19.6%

Cash flow

See full
Operating cash flow-$20.7M+52.3%
CapEx$121.0K-64.2%
Free cash flow-$20.8M+52.4%

Valuation

See full
Market cap$12.89B+52.0%
Enterprise value$12.81B+52.9%
P/S18.2×-1.4×

Profitability

See full
Gross margin92.6%+1.1pp
Operating margin-24.4%-9.3pp
Net margin-26.6%-9.8pp
FCF margin-10.2%-3.9pp

Returns & leverage

See full
Return on equity-349.4%+109pp
Debt / equity+0.1×
Current ratio1.4×-0.6×

Where this comes from

Reported directly by Axsome Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Axsome Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Axsome Therapeutics's operating lease rou assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Axsome Therapeutics's operating lease ROU assets?
Axsome Therapeutics (AXSM) reported operating lease ROU assets of $20.01M in Q1 2026.
How has Axsome Therapeutics's operating lease ROU assets changed year-over-year?
Axsome Therapeutics's operating lease ROU assets decreased by 14.1% year-over-year, from $23.29M to $20.01M.
What is the long-term trend for Axsome Therapeutics's operating lease ROU assets?
Over 5 years (2020 to 2025), Axsome Therapeutics's operating lease ROU assets has grown at a 64.4% compound annual growth rate (CAGR), from $1.74M to $20.86M.